Prescription drugs
We help navigate pharmacy benefit challenges
Milliman prescription drugs solutions

PBM contracting and management

Pharmacy plan design

Medicare Part D

Milliman prescription drugs insight

8 key ways patient cost sharing impacts life science companies
We explain key concepts and discuss several ways cost-sharing dynamics can influence decision making for life science companies.
‘Unlinking’ from the past: Measuring the potential impact from 2027 Part C and D risk adjustment model changes on Medicare Advantage Organizations
Understand how CMS's 2027 proposed risk adjustment changes could reshape Medicare Advantage reimbursement outcomes.
Milliman MedIntel Part D trend insights Q4 2025
As Medicare drug costs rise, we highlight some trends among the key populations and by product.

Approaches to lower Medicare Part D out-of-pocket costs for beneficiaries with limited income
With the sunset of two Medicare demonstration programs, states and Part D plans need to evaluate other strategies to lower cost sharing for affected individuals.

Pharmacy Briefing - March 2026
We highlight the latest pharmacy industry news, trends, and insights.
From ASP to WAC: 8 key drug pricing terms life science companies should know
We review some commonly used drug-pricing terms in the U.S. pharmaceutical market, including their calculations and roles in the healthcare industry.
Milliman MedIntel Part D trend insights Q3 2025
Drug costs are still rising, but trends begin to slow in Q3 2025
Navigating Medicare Part D settlements post-IRA: Strategic guidance for health plans
Practical considerations for financial forecasting
Adapting to the IRA: 5 manufacturer considerations for Part D formulary access negotiations
We discuss five key considerations for manufacturers negotiating Medicare Part D formulary access in the wake of the Inflation Reduction Act.
The Medicare Prescription Payment Plan: Implementation in 2025 and implications for 2026
We discuss the implementation of the Medicare Prescription Payment Plan in 2025 and note some implications for 2026.
